KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week The company previously presented data showing its first-in-class oral STAT6 degrader, KT-621, was exquisitely selective for STAT6 over other STATs and fully blocked IL-4/IL-13 functions in key human TH2 cellular assays with picomolar potency that was superior to dupilumab. In addition, at low daily ora ...

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Highlights of the KT-333 Clinical Abstract WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new Phase 1 data for KT-333, a first- in-class degrader of STAT3, highlighting safety, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | ...

Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, ...

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into the first half o ...

Financial Data and Key Metrics Changes - The company reported a cash balance of $745 million at the end of 2023, providing a runway into the first half of 2027, which supports its ambitious goals [22][44] - Research and development expenses for Q4 totaled $53 million, with an adjusted cash R&D spend of $47.7 million, reflecting a 13% increase from the same quarter last year [43][44] - The company earned $55 million in milestones from Sanofi, with $40 million recognized in Q4 and the remaining $15 million recorded as receivable [42][44] Business Line Data and Key Metrics Changes - The IRAK4 program has initiated two Phase 2 trials in hidradenitis suppurativa and atopic dermatitis, with top-line data expected in the first half of 2025 [35] - The KT-621 program, targeting STAT6, is set to enter clinical trials in the second half of 2024, with potential for a multibillion-dollar opportunity [36][37] - The oncology portfolio, including KT-333 and KT-253, is progressing through dose escalation, with additional proof of concept data expected this year [39][40] Market Data and Key Metrics Changes - The company aims to address the significant market opportunity for oral drugs in immunology, as 75% of patients taking biologics expressed a preference for oral alternatives [33][62] - The competitive landscape in immunology is noted to be growing, but the company believes it is well-positioned to offer differentiated oral therapies [116] Company Strategy and Development Direction - The company is focused on building a best-in-industry oral immunology pipeline with first-in-class programs targeting undrugged or poorly drugged targets [60][62] - The strategy includes leveraging the advantages of protein degraders to provide biologics-like specificity and activity while maintaining the convenience of oral administration [24][31] - The company is committed to exploring additional indications for its programs, including potential expansions beyond skin indications for IRAK4 [47][63] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the immunology programs and the potential to change treatment paradigms for immune-mediated diseases [9][34] - The company anticipates significant data releases in 2024 and 2025 that could impact its development strategy and market positioning [9][66] - Management emphasized the importance of data-driven decisions for advancing programs in both immunology and oncology [84][110] Other Important Information - The company plans to present preclinical data from the STAT6 and TYK2 programs at multiple scientific meetings this year [38] - The company has reached targeted degradation levels in clinical settings, with over 90% degradation achieved in the STAT3 program [95][121] Q&A Session Summary Question: What will inform the decision-making for the IRAK4 program's future indications? - Management indicated that the data from ongoing trials will guide decisions on potential expansions into respiratory, rheumatology, or GI indications [47] Question: How does the company view the competitive landscape for STAT6 and TYK2? - Management noted that while the landscape is competitive, there is significant white space for oral drugs with good safety profiles, positioning the company favorably [116] Question: What are the criteria for advancing the oncology programs? - The decision to advance will be based on data indicating opportunities to impact broad patient populations in both hematological and solid tumors [84][110]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 Additional KT-333 (STAT3) and KT-253 (MDM2) Phase 1 data expected in 2024 Watertown, Mass. (February 22, 2024) – Kymera ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B. Riley Securities Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...